Page 102 - 88_01

Circ Cardiovasc Qual Outcomes. 2010;3(4):395–405.
57. García Rodríguez LA, Tacconelli S, Patrignani P. Role of Dose Potency
in the Prediction of Risk of Myocardial Infarction Associated With
Nonsteroidal Anti-Inflammatory Drugs in the General Population. J
Am Coll Cardiol. 2008;52(20):1628–36.
58. García-Poza P, de Abajo FJ, Gil MJ, Chacón A, Bryant V, García-Ro-
dríguez LA. Risk of ischemic stroke associated with non-steroidal
anti-inflammatory drugs and paracetamol: A population-based case-
control study. J Thromb Haemost. 2015;13(5):708–18.
59. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen
ML, Fosbol EL, et al. Increased mortality and cardiovascular morbi-
dity associated with use of nonsteroidal anti- inflammatory drugs
in chronic heart failure. Arch Intern Med. 2009;169(2):141–9.
60. Goodson NJ, Brookhart AM, Symmons DPM, Silman AJ, Solomon
DH. Non-steroidal anti- inflammatory drug use does not appear
to be associated with increased cardiovascular mortality in pa-
tients with inflammatory polyarthritis: results from a primary care
based inception cohort of patients. Ann Rheum Dis.
2009;68(3):367–72.
61. Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy
G, et al. Risk of acute myocardial infarction and sudden cardiac
death in patients treated with cyclo-oxygenase 2 selective and non-
selective non-steroidal anti-inflammatory drugs: nested case-control
study. Lancet. 2005;365(9458):475–81.
62. Grimaldi-Bensouda L, Rossignol M, Danchin N, Steg PG, Bessede G,
Ovize M, et al.. Risk of ST versus non-ST elevation myocardial in-
farction associated with non-steroidal anti- inflammatory drugs.
Heart. 2011;97(22):1834–40.
63. Haag MDM, Bos MJ, Hofman A, Koudstaal PJ, Breteler
MMB, Stricker BHC. Cyclooxygenase selectivity of nonsteroidal
anti-inflammatory drugs and risk of stroke. Arch Intern Med.
2008;168(11):1219–24.
64. Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos JM, Klaukka
T, Idänpään-Heikkilä JE, et al.. NSAID use and the risk of hospita-
lization for first myocardial infarction in the general population:
A nationwide case-control study from Finland. Eur Heart
J. 2006;27(14):1657–63.
65. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA.
Non-steroidal anti- inflammatory drugs and risk of first hospital ad-
mission for heart failure in the general population. Heart.
2006;92(11):1610–5.
66. Johnsen SP. Risk of Hospitalization for Myocardial Infarction Among
Users of Rofecoxib, Celecoxib, and Other NSAIDs. Arch Intern Med.
2005;165(9):978.
67. Kim J, Lee J, Shin CM, Lee DH, Park B-J. Risk of gastroin-
testinal bleeding and Res Care. 2015;3(1):e000133.
68. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J,
100 Analysis and evaluation of cardiovascular and gastrointestinal risk of nonsteroidal
anti-inflammatory drugs selective and non-selective cyclooxygenase inhibitors
Antonio Margo
An. Real Acad. Farm.Vol. 88. nº 1 (2022) · pp. 85-103
ANALES
RANF
www.analesranf.com
et al.. Exposed to rofecoxib and celecoxib have different odds of non-
fatal myocardial infarction. Ann Intern Med. 2005;142(3):157–
64.
69. Kohli P, Steg PG, Cannon CP, Smith SC, Eagle KA, Ohman EM, et al..
NSAID use and association with cardiovascular outcomes in outpa-
tients with stable atherothrombotic disease. Am J Med.
2014;127(1).
70. Krijthe BP, Heeringa J, Hofman A, Franco OH, Stricker BH. Non-ste-
roidal anti-inflammatory drugs and the risk of atrial fibrillation:
a population-based follow-up study. BMJ Open.
2014;4(4):e004059.
71. Lamberts M, Lip GYH, Hansen ML, Lindhardsen J, Olesen JB, Rauns
J, et al.. Relation of nonsteroidal anti-inflammatory drugs to se-
rious bleeding and thromboembolism risk in patients with atrial
fibrillation receiving antithrombotic therapy: A nationwide cohort
study. Ann Intern Med. 2014;161(10):690–8.
72. Lapi F, Piccinni C, Simonetti M, Levi M, Lora Aprile P, Cricelli I, et
al.. Non-steroidal anti- inflammatory drugs and risk of cerebrovas-
cular events in patients with osteoarthritis: a nested case-control
study. Intern Emerg Med. 2016;11(1):49–59.
73. Laredo L, Rodríguez Á, Vargas E, Moreno A, Cruz A, Dios García J
De. Asociación entre consumo de antiinflamatorios no esteroideos
e insuficiencia cardíaca congestiva. Med Clin (Barc).
2003;120(17):658–60.
74. Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on Mortality and the
Effect of Preexisting Coronary Artery Disease in US Veterans. Am J
Med. 2007;120(1):9–16.
75. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction
with cyclooxygenase-2 inhibitors: a population study of elderly
adults. Ann Intern Med. 2005;142(7):481–9.
76. Lindhardsen J, Gislason GH, Jacobsen S, Ahlehoff O, Olsen A-MS,
Ole Rintek Madsen, et al. Non-steroidal anti-inflammatory drugs
and risk of cardiovascular disease in patients with rheumatoid arth-
ritis: a nationwide cohort study. Ann Rheum Dis.
2014;73(8):1515–21.
77. Liu SS, Bae JJ, Bieltz M, Ma Y, Memtsoudis S. Association of Perio-
perative Use of Nonsteroidal Anti-Inflammatory Drugs With Posto-
perative Myocardial Infarction After Total Joint Replacement. Reg
Anesth Pain Med. 2012;37(1):45–50.
78. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie
G, et al.. Effect of selective cyclooxygenase 2 inhibitors and naproxen
on short-term risk of acute myocardial infarction in the elderly. Arch
Intern Med. 2003;163(4):481–6. Inhibitors versus non-selective
non-steroidal anti-inflammatory drugs and congestive heart failure
outcomes in elderly patients: a population-based cohort study. Lan-
cet. 2004;363(9423):1751–6.
80. Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use